TAS-102

Hi,

The FDA will make a final approval decision on TAS-102 by December 19, 2015.

Study results:

For patients treated with TAS-102, the median overall survival was 7.1 months compared with 5.3 months with placebo (HR = 0.68; P <.0001). The median PFS in the TAS-102 arm was 2 months versus 1.7 months with placebo - See more at: http://www.onclive.com/web-exclusives/FDA-Accepts-NDA-for-TAS-102-in-mCRC#sthash.k85yXXP2.dpuf

Take a look at this link for a comprehensive description:

http://www.onclive.com/web-exclusives/FDA-Accepts-NDA-for-TAS-102-in-mCRC